Antikoagulation, Aggregationshemmer, Fibrinolyse

  • B. Ritter
Part of the Handbuch der inneren Medizin book series (INNEREN, volume 9 / 3)

Zusammenfassung

Pathologisch-anatomisches Substrat der Therapie mit gerinnungsbeeinflussenden Medikamenten ist das Blutgerinnsel. Durch Fibrinolytika soll das Fibringerinnsel wieder aufgelöst werden, Antikoagulantien sollen seine Bildung verhindern und die Aggregationshemmer durch eine Änderung der Thrombozyteneigenschaften eventuell auch die Progression der koronaren Herzkrankheit beeinflussen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aber CP, Bass NM, Berry CL, Carson PHM, Dobbs RJ, Fox KM, Hamblin JJ, Haydn SP, Howitt G, Macver JE, Portal RW, Raftery GB, Roussell RH, Stock JPP (1976) Streptokinase in acute myocardial infarction: A controlled multicentre study in the United Kingdom. Br Med J 2: 1100–1104Google Scholar
  2. Anschüz F, Hensel W-H (1973) Antikoagulantien nach Myokardinfarkt: Durchführung und Beurteilung der Dauertherapie. Diagnostik 6: 231–233Google Scholar
  3. Anturane Reinfarction Trial Research Group (1980) Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302: 250–256CrossRefGoogle Scholar
  4. Anturane Reinfarction Italian Study Group (1982) Sulfinpyrazon in post-myocardial infarction. Lancet 1982 /1: 237–242Google Scholar
  5. Aspirin Myocardial Infarction Study Research Group (1980) A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243: 661–669CrossRefGoogle Scholar
  6. Beck OA, Nunberger D, Hochrein H (1978) Initiale Heparintherapie und orale Antikoagulantien beim akuten Myokardinfarkt. Med Welt 29: 232–236PubMedGoogle Scholar
  7. Bell WR, Royall RM (1980) Heparin-associated thrombozytopenia: A comparison of three heparin preparations. N Engl J Med 303: 902–907Google Scholar
  8. Benda L, Haider M, Ambrosch F (1977) Ergebnisse der österreichischen Herzinfarktstudie mit Streptokinase. Wien Klin Wochenschr 89: 779–783PubMedGoogle Scholar
  9. Bett JHN (1977) Australian multicentre trial of streptokinase in acute myocardial infarction. Med J Austr 1: 553–555Google Scholar
  10. Chalmers ThC, Matta RJ, Smith H, Kunzler A-U (1977) Evidence favouring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 297: 1091–1096PubMedCrossRefGoogle Scholar
  11. Connfleld J(1951)A method of estimating comparative rates from clinical data: Applica-tions to cancer of the lung, brest and cervix: J Natl Cancer Inst 2:1269–1271Google Scholar
  12. Cooperative Clinical Trial Group (1973) Anticoagulants in acute myocardial infarction. Results of a cooperative clinical trial. JAMA 225: 724–729CrossRefGoogle Scholar
  13. Coronary Drug Project Research Group (1976) Aspirin in the coronary heart disease. J Chronic Dis 29: 625–642CrossRefGoogle Scholar
  14. Craven LL (1953) Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Med J 75: 38–44Google Scholar
  15. Curtin T, Mulhern B (1980) Foetal warfarin syndrome. Ir Med J 73: 393–394PubMedGoogle Scholar
  16. Deutsch E (1977) Die Stellung der gerinnungshemmenden Therapie in der Behandlung des Myokardinfarktes. In: Schettler G, Horsch A, Morl H, Orth H, Weizel A (Hrsg) Der Herzinfarkt. Schattauer, Stuttgart New York, S 379–389Google Scholar
  17. Dioguardi N, Lotto A, Levi GF, Rota M, Proto C, Mannucci PM, Rossi P, Lomanto B, Mattei G, Fiorelli G, Agostini A (1971) Controlled trial of streptokinase and heparin in acute myocardial infarction. Lancet 1971 /2: 891–895CrossRefGoogle Scholar
  18. Douglas AG, McNicol GP (1976) In: Biggs R (ed) Human blood coagulation, haemostasis and thrombosis. Blackwell, pp 557–564Google Scholar
  19. Drapkin A, Merskey L (1972) Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient’s age, sex, and severity of infarction. J Am Med Ass 222: 541–542Google Scholar
  20. Dukert F, Market GA (1977) Die Kontrolle der oralen Antikoagulantien: der therapeutische Bereich. Rundschau Med (Praxis) 66: 293–294Google Scholar
  21. Elwood PC, Sweetnam PM (1979) Aspirin and secondary mortality after myocardial infarction. Lancet 11: 1313–1315CrossRefGoogle Scholar
  22. Elwood PC, Williams WO (1979) A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J R Col Gen Pract 29: 413–416Google Scholar
  23. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Wilhams G, Welsby L, Hughes SI, Renton R (1974) A randomized trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1: 436–440PubMedCrossRefGoogle Scholar
  24. Emerson PA (1978) Preventing thromboembolism after myocardial infarction: Effect of low-dose heparin or smoking. Am Heart J 96: 129PubMedCrossRefGoogle Scholar
  25. EPSIM Research Group (1982) A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 307: 701–708CrossRefGoogle Scholar
  26. European Collaborative Study Group (1975) Controlled trial of urokinase in acute myocardial infarction. A european collaborative study. Lancet II: 624–626Google Scholar
  27. European Cooperative Study Group (1979) Streptokinase in acute myocardial infarction. N Engl J Med 15: 797–802Google Scholar
  28. FDA Drug Bulletin (1978) Sulfinpyrazone and prevention of myocardial infarction. May/ July 1978, pp 19–20Google Scholar
  29. Fletcher AP, Sherry S, Alkjeaersis N, Smyrniotis FE, Jick S (1959) The maintainance of sustained thrombolytic state in man (II). Clinical observation on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 38: 1111–1119Google Scholar
  30. Forfar JC (1979) A 7-year analysis of haemorrhase in patients on long-term anticoagulant treatment. Br Heart J 42: 128–132PubMedCrossRefGoogle Scholar
  31. Fulton RM, Duckett K (1976) Plasma-fibrinogen and thromboemboli after myocardial infarction. Lancet II: 1161–1164Google Scholar
  32. Gallus AG, Hirsch J, Tutle RJ, Trebilcock R, O’Brien GE, Carroll JJ, Minden JH, Hudecki SM (1973) Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 288: 545–551PubMedCrossRefGoogle Scholar
  33. Genton E (1980) A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease. Circulation [Suppl V] 62: 111–121Google Scholar
  34. Goldman L, Feinstein AR (1979) Anticoagulants and myocardial infarction. The problem of pooling, drowing and floaring. Ann Intern Med 90: 92–94Google Scholar
  35. Griffith EH, Hero N (1979) Chronic use of anticoagulants, psychosocial adaptation. NY State J Med pp 90–92Google Scholar
  36. Handley AJ (1972) Heparin in the prevention of deep vein thrombosis after myocardial infarction. Br Med J II: 436–438Google Scholar
  37. Heene DL (1980) Cumarin-Derivate: Ärztliche Überwachung. Aus: Kontrolle von An- tithrombotika. In: Marx R, Thies HA (Hrsg) XXIII Hamburger Symposium über Blutgerinnung. Editiones Roche, S 131–135Google Scholar
  38. Heene DL, Schöndorf Th, Matthias FR (1977) Antikoagulantienanwendung in der Inneren Medizin. Klinische Indikationen, Kontraindikationen und Ergebnisse. In: Marx R, Thiess HA (Hrsg) Klinische und ambulante Anwendung klassischer Antikoagulantien. Schattauer, Stuttgart New York, S 91–111Google Scholar
  39. Hilden T, Iversen L, Raaschou F, Schwartz M (1961) Anticoagulants in acute myocardial infarction. Lancet 1: 327–330CrossRefGoogle Scholar
  40. Hoppe J, Maaß H (1982) Hepatitisrisiko von konventionellen PPS B-Poolpräparaten. Dtsch Med Wochenschr 107: 1966–1968PubMedCrossRefGoogle Scholar
  41. Hurst JW, Logue RB, Walter PF (1978) The clinical recognition and medical management of coronary atherosclerotic heart disease. In: Hurst JW (ed) The Heart. 4th edn. McGraw Hill, New York, pp 1156–1291Google Scholar
  42. International Anticoagulant Review Group (1970) Collaborative analysis of long term anticoagulant administration after acute myocardial infarction. Lancet 1: 203–209Google Scholar
  43. Link KP (1959) The discovery of dicumarol adits sequels. Circulation 19: 97–107PubMedGoogle Scholar
  44. Linos A, Worthington JW, O’Fallon W, Fuster V, Whisnant JP, Kurland LT (1978) Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. Mayo Clin Proc 53: 581–584Google Scholar
  45. Loeliger EA (1961) Der holländische Thrombosedienst. Wien Klin Wochenschr 51: 915–923Google Scholar
  46. Loeliger EA (1983) Oral anticoagulants and/or aspirin. In: Roskamm H (ed) Prognosis of coronary heart disease - progression of coronary arteriosclerosis. Springer, Berlin Heidelberg New York, p 223CrossRefGoogle Scholar
  47. Madhock RK, Sharma SK (1978) Rheologische Veränderungen des Blutes beim akuten Myokardinfarkt. Schwerpunkt Med 2: 93–95Google Scholar
  48. Mallory TB (1939) Am Heart J 17: 667Google Scholar
  49. Mannucci PM (1972) Streptokinase in recent myocardial infarction: Short and long-term evaluation. Abstractbook, III Congress of the International Society of Thrombosis and Haemostasis, Washington DC, p 434Google Scholar
  50. Maunt MJ, Thong KL, Birthwhistle RV, Brain BD, Hammond GW, Grace MG (1977) Haemorrhagic complications of heparintherapy. Lancet 1977 /1: 1133–1135CrossRefGoogle Scholar
  51. May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL (1982) Secondary prevention after myocardial infarction: A review of long-term trials. Progr Cardiovsc Dis 24: 331–352CrossRefGoogle Scholar
  52. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y, Thompson SG (1980) Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1: 1050–1053Google Scholar
  53. Meyer J, Merx W, Schweizer P, Erbel R, Schmitz HJ, Dörr R, Messmer BJ, Effert S (1982) Ballondilatation und Operation als Anschlußmaßnahme nach erfolgreicher Thrombolyse. Z Kardiol 71: 591 (abstr)Google Scholar
  54. Nicolaides AN, Kakkar VY, Renney JTG, Kidner PH, Hutchinson PCS, Clarke MB (1971) Myocardial infarction and deep-vein thrombosis. Br Med J 1971 /1: 432–436CrossRefGoogle Scholar
  55. O’Grady J, Moucada S (1959) Aspirin: A paradoxical effect on bleeding time. Lancet 11: 780Google Scholar
  56. Owren PA (1959) Thrombotest: A new method for controlling anticoagulant-therapy. Lancet 1959 /2: 754–755CrossRefGoogle Scholar
  57. Packham MA, Mustard JF (1980) Pharmacology of platelet affecting drugs. Circulation 62 [Suppl V]: 26–41Google Scholar
  58. Passamani ER (1980) Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease. Circulation 62 [Suppl V]: 106–110Google Scholar
  59. Quick AJ (1935) The prothrombin in haemophilia and in obstructive jaundice. J Biol Chem 73: 109–111Google Scholar
  60. Rentrop P, Blanke H, Karsch KR, Kaiser H, Köstering H, Leitz K (1981) Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 63: 307–317PubMedCrossRefGoogle Scholar
  61. Ritter B, Schöll V, Gohlke H, Betz P, Budde U, Roskamm H (1982) Normalisierung des belastungsinduzierten Anstiegs von Plättchenfaktor 4 bei Patienten mit Herzinfarkt unter 40 Jahren. Verh Dtsch Ges Inn Med 88: 1153–1156Google Scholar
  62. Roberts WC, Ferrans VJ (1976) The role of thrombosis in the etiology of atherosclerosis (a positive one) and in precipitating fatal ischemic heart disease (a negative one). In: Donoso E, Haft JI (eds) Current cardiovascular topics II: Thrombosis, platelets, anticoagulation and acetylsalicylic acid. Thieme, Stuttgart, pp 143–155Google Scholar
  63. Roskamm H, Gohlke H, Stürzenhofecker P, Droste C, Thomas H, Samek L, Schnellbacher K, Betz P (1983) Der Herzinfarkt im jugendlichen Alter (unter 40 Jahren): Koronarmorphologie, Risikofaktoren, Langzeitprognose der Erkrankung und Progression der Koronargefäßsklerose. Z Kardiol 72: 1–11Google Scholar
  64. Russo JV, Margolis S, Friesinger GC, Ross RS (1970) Heparin and ventricular arrhythmias after myocardial infarction. Lancet II: 1271–1275CrossRefGoogle Scholar
  65. Salzmann EW, Deykin D, Shapiro RM, Rosenberg R (1975) Management of heparin therapy: Controlled prospective trial. N Engl J Med 292: 1046–1050CrossRefGoogle Scholar
  66. Schmutzler R, Heckner F, Körtge P, van de Loo J, Petzold FA, Pretorius F, Polivoda H, Zekorn D (1966) Zur fibrinolytischen Therapie des frischen Herzinfarktes. Dtsch Med Wochenschr 91: 581–585Google Scholar
  67. Schmutzler R, Fritze E, Gebauer D, Gillmann H, Heckner F, Körtge P, van de Loo J, Petzold FA, Polivoda H, Prätorius F, Zekorn D (1971) Fibrinolytic therapy in acute myocardial infarction. Thrombos Diathesis Haemorrh 47 [Suppl]: 211–215Google Scholar
  68. Schröder R, Biamino G, Leitner ER v, Linderer Th, Hertz J, Vöhringer HF, Wegscheider K, Andresen D, Arntz HR, Brüggemann Th, Grassot A, Lichey J, Oeff M, Prokein E, Schäfer JH, Sörensen R (1982) Systemische Thrombolyse mit Streptokinase-Kurz- infusion beim akuten Myokardinfarkt. Z Kardiol 71: 703–718Google Scholar
  69. Selzer A (1978) Use of anticoagulant agents in acute myocardial infarction: Statistics or clinical judgement? Am J Cardiol 41: 1315–1317PubMedCrossRefGoogle Scholar
  70. Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt SD, Sisk C, Baskin WN, Mackerchier PA, Hewett J (1979) Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 91: 517–520PubMedGoogle Scholar
  71. Sixty Plus Reinfarction Study Group (1980) A double-blind trial to assess longterm anticoagulant therapy in elderly patients after myocardial infarction. Lancet II: 989–993Google Scholar
  72. Stevenson RE, Burton OM, Ferlanto GJ, Taylor HA (1980) Hazards of oral anticoagulants during pregnancy. J Am Med J 243: 1549–1551Google Scholar
  73. Temple R, Pledger GW (1980) The FDA’s critique of the Anturane Reinfarction Trial. N Engl J Med 303: 1488–1492PubMedCrossRefGoogle Scholar
  74. The Persantine-Aspirin Reinfarction Study Group (1980) Pergantine and aspirin in coronary heart disease. Circulation G2: 449–461Google Scholar
  75. Theiss G, Vogler E, Wirtzfeld A, Keisel I, Blömer H (1980) Gerinnungsbefunde und rheologische Messungen bei Streptokinasebehandlung des akuten Myokardinfarktes. Klin Wochenschr 58: 607–615PubMedCrossRefGoogle Scholar
  76. Überla K (1978) Multicenter two-year prospective study on the prevention of secondary myocardial infarction by ASA in comparison with phenprocumon and placebo. In: Breddin K, Dorndorf W, Loew D, Marx R (eds) Acetylsalicylic acid in cerebral ischemia and coronary heart disease. Schattauer, Stuttgart, pp 157–169Google Scholar
  77. Verstraete M (1971) Streptokinase in recent myocardial infarction. A controlled multicentre trial. Br Med J 3: 325–331CrossRefGoogle Scholar
  78. Veterans Administration Cooperative Clinical Trial (1973) J Am Med Ass 225: 724CrossRefGoogle Scholar
  79. Warlow C, Terry G, Kenmore ACF, Beattie AG, Douglas AG (1973) A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1: 934–936CrossRefGoogle Scholar
  80. Wray R, Maurer B, Shillingford J (1973) Prophylactic anticoagulant therapy in the prevention of calfvein thrombosis after myocardial infarction. N Engl J Med 288: 815–817PubMedCrossRefGoogle Scholar
  81. Wright IG, Marple CD, Beck DF (1948) Report of the committee for the evaluation of anticoagulants in the treatment of coronary thrombosis with myocardial infarction. Am Heart J 36: 801–815PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • B. Ritter

There are no affiliations available

Personalised recommendations